EUVIMEDEUVIMED entdecken
Crossref

Immunohistochemical expression of EZH2 in germ cell tumors of the testis: New insights into the genesis and epigenetic reprogramming of these fascinating tumors

Sofia Melotti, Francesca Ambrosi iD, Tania Franceschini iD, Francesca Giunchi iD, Francesco Vasuri iD, Agnese Orsatti iD, Luisa Di Sciascio iD, Alessia Grillini, Eugenia Franchini, Francesco Massari iD, Veronica Mollica iD, Andrea Marchetti iD und 6 weitere

American Journal of Clinical Pathology · 2025

DOI: 10.1093/ajcp/aqaf098 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Clinical Pathology, 2025. Verfasst von Sofia Melotti und 17 weiteren Autor:innen. Beteiligte Einrichtung: Pathology Unit, DIAP-Dipartimento Interaziendale di Anatomia Patologica di Bologna, Maggiore Hospital-AUSL Bologna, Bologna, Italy. Hauptthemen laut MEDLINE: Enhancer of Zeste Homolog 2 Protein, Testicular Neoplasms, Neoplasms, Germ Cell and Embryonal. Die Arbeit nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Several studies analyzed the “reprogramming” of germ cell tumors of the testis (GCTT), known to be an epigenetic process that results in the preservation of stem cell features and/or differentiation of GCTT. EZH2 is a methyltransferase involved in the epigenetic regulation of tumors and has become a promising therapeutic target, but few studies have analyzed its expression in GCTT, germ cell neoplasia in situ (GCNIS), and adjacent testis.

Methods

We tested 131, 36, and 29 GCTT components, GCNIS, and adjacent testes, respectively. EZH2 expression was evaluated by H-score and compared between different subgroups by adopting median values and the Fisher exact test.

Results

We found that EZH2 was more highly expressed by adjacent testis/GCNIS rather than by GCTT (P < .001), with adjacent testis showing the highest values and being statistically significant compared to GCNIS (P < .001). In adjacent testis, EZH2 expression was mainly detected in spermatocytes (primary and secondary) and spermatids, with scattered positive spermatogonia. Seminoma/embryonal carcinoma showed statistically significantly higher EZH2 expression compared to the other nonseminomatous GCTT (P = .027).

Conclusions

EZH2 is differentially expressed during GCTT reprogramming (adjacent testis [very high levels] → GCNIS [high levels] → seminoma/embryonal carcinoma [moderate levels] → other nonseminomatous GCTT [low/absent levels]), supporting its involvement in the epigenetic regulation for determining the fate of GCTT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Enhancer of Zeste Homolog 2 ProteinTesticular NeoplasmsNeoplasms, Germ Cell and EmbryonalMaleHumansEpigenesis, GeneticImmunohistochemistryAdultTestisSeminomaBiomarkers, TumorMiddle Aged

Stichwörter der Autor:innen

EZH2germ cell neoplasia in situgerm cell tumors of the testisreprogrammingseminoma

Substanzen

Enhancer of Zeste Homolog 2 ProteinEZH2 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Pathology Unit, DIAP-Dipartimento Interaziendale di Anatomia Patologica di Bologna, Maggiore Hospital-AUSL Bologna, Bologna, Italy.
  • Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
  • Pathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Pathology Unit, Santa Maria delle Croci Hospital, Ravenna, Italy.
  • Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Urology Department, Maggiore Hospital-AUSL Bologna, Bologna, Italy.

ORCID-Profile: Francesca Ambrosi, Tania Franceschini, Francesca Giunchi, Francesco Vasuri, Agnese Orsatti, Luisa Di Sciascio, Francesco Massari, Veronica Mollica, Andrea Marchetti, Federico Mineo Bianchi, Maurizio Colecchia, Andres Martin Acosta, João Lobo, Michelangelo Fiorentino, Costantino Ricci

Zitieren

APA

Melotti, S., Ambrosi, F., Franceschini, T., Giunchi, F., Vasuri, F., Orsatti, A., Di Sciascio, L., Grillini, A., Franchini, E., Massari, F., Mollica, V., Marchetti, A., Mineo Bianchi, F., Colecchia, M., Acosta, A. M., Lobo, J., Fiorentino, M., & Ricci, C. (2025). Immunohistochemical expression of EZH2 in germ cell tumors of the testis: New insights into the genesis and epigenetic reprogramming of these fascinating tumors. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqaf098

Vancouver

Melotti S, Ambrosi F, Franceschini T, Giunchi F, Vasuri F, Orsatti A, et al. Immunohistochemical expression of EZH2 in germ cell tumors of the testis: New insights into the genesis and epigenetic reprogramming of these fascinating tumors. American Journal of Clinical Pathology. 2025. doi:10.1093/ajcp/aqaf098

BibTeX
@article{Melotti2025,
  author = {Melotti, Sofia and Ambrosi, Francesca and Franceschini, Tania and Giunchi, Francesca and Vasuri, Francesco and Orsatti, Agnese and Di Sciascio, Luisa and Grillini, Alessia and Franchini, Eugenia and Massari, Francesco and Mollica, Veronica and Marchetti, Andrea and Mineo Bianchi, Federico and Colecchia, Maurizio and Acosta, Andres Martin and Lobo, João and Fiorentino, Michelangelo and Ricci, Costantino},
  title = {Immunohistochemical expression of EZH2 in germ cell tumors of the testis: New insights into the genesis and epigenetic reprogramming of these fascinating tumors},
  journal = {American Journal of Clinical Pathology},
  year = {2025},
  doi = {10.1093/ajcp/aqaf098}
}
Kostenlos starten →